K36 Therapeutics, Inc., a clinical-stage biotech company focused on developing its MMSET inhibitor KTX-1001 for genetic translocation t(4;14) multiple myeloma, appointed Benjamin Winograd, chief medical officer to lead the medical and clinical teams. Winograd joins K36 with a track record of bringing innovative medicines for hematological and solid tumor disease treatments to patients. Previously, Winograd worked at Celgene where, as vice president of clinical development and head of clinical...